Among 31 consecutive @entity1 who developed @entity3052 following treatment with chemotherapy or radiation therapy, 17 were treated with intensive chemotherapy aimed at inducing a complete remission. Seven of these 17 @entity1 (41%) obtained a complete remission that ranged in duration from 2 to 11 (median 3) months. Two additional @entity1 who failed to develop normal peripheral blood counts despite postinduction bone marrows that were normocellular and free of @entity1778 were classified as nonresponders. The median time to complete remission and median duration of @entity1431 (WBC less than 1,000/ @entity9164 ) were 34 days and 23 days, respectively. Induction chemotherapy was complicated by fever in all @entity1 , documented @entity281 in six @entity1 , and @entity204 secondary to sepsis in three. Survival of the 17 @entity1 ranged from less than 1 to 39 (median 4) months. @entity1 achieving a complete remission had a median survival time of 10 months compared to 2 months for the nonresponders. The other 14 @entity1 received only supportive care and had a median survival of 2 months. These findings indicate that therapy-associated @entity3052 (t-ANLL) can frequently respond to chemotherapy and that achieving a complete remission is associated with longer survival. Although these results are encouraging, @entity1 with t-ANLL still have a relatively poor prognosis and efforts directed at improving treatment outcome need to be continued.

Response of therapy-associated XXXX to intensive induction chemotherapy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute nonlymphocytic leukemia'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity9164 :: ('2944', 'Gene') :: ['mu 1'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity3052 :: (MESH:D015470,Disease) :: ['acute nonlymphocytic leukemia']
